Marcelo Garrido
0000-0001-8905-8986
Publication & Citation Trends
Publications
277 total
First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial.
Cited by 1
Semantic Scholar
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial OA
Cited by 18
Semantic Scholar
Mo1250 PATHOLOGICAL COMPLETE RESPONSE (PCR) TO DURVALUMAB PLUS 5-FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND DOCETAXEL (FLOT) IN RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER (GC/GEJC): INTERIM RESULTS OF THE GLOBAL, PHASE 3 MATTERHORN STUDY
Cited by 0
Semantic Scholar
178P KEYNOTE-859 update: Pembrolizumab + chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
Cited by 0
Semantic Scholar
419P Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4-year (y) follow-up (FU) of CheckMate 649
Cited by 0
Semantic Scholar
680. P02.06 MATTERHORN PCR BY REGION OA
Cited by 0
Semantic Scholar
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial PDF
Cited by 2,790
OpenAlex
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial PDF
Cited by 2,902
OpenAlex
Research Topics
Gastric Cancer Management and Outcomes
(106)
Cancer Immunotherapy and Biomarkers
(68)
Esophageal Cancer Research and Treatment
(40)
Colorectal Cancer Treatments and Studies
(37)
Gastrointestinal Tumor Research and Treatment
(37)
Affiliations
Universidad de Santiago de Chile
Twitter (United States)
Universidad Mayor
Memorial Sloan Kettering Cancer Center
Valparaiso University